EGFR and non-small cell lung carcinoma: The subgroup analysis of different EGFR-mAbs showed that patients with NSCLC in the cetuximab plus chemotherapy subgroup[16,17,25,36,37] and the necitumumab plus chemotherapy subgroup[18–20,26] had remarkably improved OS.